ArticlePituitary2026
Sustained remission of chronic post-traumatic arginine vasopressin deficiency despite absent posterior pituitary bright spot on MRI: a case series.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbsence of the posterior pituitary bright spot (PPBS) on T1-weighted MRI is often observed in chronic post-traumatic arginine vasopressin deficiency (AVP-D), but its association with permanent AVP-D remains unclear. CASE PRESENTATION: We report five patients with chronic-phase post-traumatic AVP-D (156-965 days post-injury) who were transferred to our rehabilitation center. All patients had received long-term desmopressin therapy and exhibited persistent absence of the PPBS on T1-weighted MRI at admission. Despite these findings, desmopressin therapy was successfully tapered and discontinued in all five cases. Case 3 presented a diagnostic challenge, in which resolution of post-traumatic AVP-D was obscured by concomitant adrenal insufficiency and was confirmed only after stabilization of glucocorticoid replacement. In Cases 3, 4, and 5, detectable plasma arginine vasopressin levels (1.0-1.9 pg/mL) were observed following desmopressin withdrawal despite persistent radiologic absence of the PPBS. All patients maintained stable water balance without desmopressin therapy, with no recurrence of polyuria or clinically significant hypernatremia during follow-up.
conclusionEndogenous vasopressin secretion may be retained in selected patients with chronic TBI, even when MRI suggests persistent neurohypophyseal abnormalities. Our cases demonstrate that absence of the PPBS is not a definitive marker of lifelong post-traumatic AVP-D. These observations support periodic reassessment and supervised trial discontinuation of desmopressin therapy in the neurorehabilitation setting, suggesting that preserved endogenous vasopressin function may remain unrecognized years after the initial insult.
Indexed as
Identifiers
42435120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.